Home

About

Advanced Search

Browse by Discipline

Scientific Societies

E-print Alerts

Add E-prints

E-print Network
FAQHELPSITE MAPCONTACT US


  Advanced Search  

 
In Vivo Evaluation of Pretargeted 64Cu for Tumor Imaging and Therapy
 

Summary: In Vivo Evaluation of Pretargeted 64Cu for
Tumor Imaging and Therapy
Michael R. Lewis, PhD1; Mu Wang, MD1; Donald B. Axworthy, BS2; Louis J. Theodore, PhD2;
Robert W. Mallet, BS2; Alan R. Fritzberg, PhD2; Michael J. Welch, PhD1; and Carolyn J. Anderson, PhD1
1Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri;
and 2NeoRx Corporation, Seattle, Washington
Pretargeting involves administration of a tumor-targeting mono-
clonal antibody (mAb) covalently linked to a molecule having a
high-affinity binding site for a rapidly distributed radiolabeled
effector molecule. The aim of this study was to compare pre-
targeting to a conventionally labeled antibody for tumor target-
ing of the intermediate-lived radionuclide 64Cu, which has
shown promise for PET imaging and radioimmunotherapy of
cancer. Methods: DOTA-biotin (where DOTA is 1,4,7,10-tet-
raazacyclododecane-N,N ,N ,N -tetraacetic acid) and the in-
tact immunoconjugate DOTA-NR-LU-10 were labeled to high
specific activities with 64Cu, and the serum stabilities and target
binding capabilities of each agent were assayed in vitro. Nude
mice bearing SW1222 human colorectal carcinoma xenografts
were administered 64Cu-DOTA-biotin, with and without pretreat-

  

Source: Anderson, Carolyn J. - Department of Molecular Biology and Pharmacology, Washington University in St. Louis

 

Collections: Biology and Medicine